Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind, U.S. Phase II trial in 149 elderly primary insomnia patients with daytime sleepiness, both doses of EVT 201 (1.5
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury